<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35248780</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-3649</ISSN><JournalIssue CitedMedium="Internet"><Volume>144</Volume><PubDate><Year>2022</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Vascular pharmacology</Title><ISOAbbreviation>Vascul Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Endothelial dysfunction in acute and long standing COVID-19: A prospective cohort study.</ArticleTitle><Pagination><StartPage>106975</StartPage><MedlinePgn>106975</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vph.2022.106975</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1537-1891(22)00024-6</ELocationID><Abstract><AbstractText Label="BACKGROUND">Coronavirus disease-19 (COVID-19) is implicated by active endotheliitis, and cardiovascular morbidity. The long-COVID-19 syndrome implications in atherosclerosis have not been elucidated yet. We assessed the immediate, intermediate, and long-term effects of COVID-19 on endothelial function.</AbstractText><AbstractText Label="METHODS">In this prospective cohort study, patients hospitalized for COVID-19 at the medical ward or Intensive Care Unit (ICU) were enrolled and followed up to 6&#xa0;months post-hospital discharge. Medical history and laboratory examinations were performed while the endothelial function was assessed by brachial artery flow-mediated dilation (FMD). Comparison with propensity score-matched cohort (control group) was performed at the acute (upon hospital admission) and follow-up (1 and 6&#xa0;months) stages.</AbstractText><AbstractText Label="RESULTS">Seventy-three patients diagnosed with COVID-19 (37% admitted in ICU) were recruited. FMD was significantly (p&#xa0;&lt;&#xa0;0.001) impaired in the COVID-19 group (1.65&#xa0;&#xb1;&#xa0;2.31%) compared to the control (6.51&#xa0;&#xb1;&#xa0;2.91%). ICU-treated subjects presented significantly impaired (p&#xa0;=&#xa0;0.001) FMD (0.48&#xa0;&#xb1;&#xa0;1.01%) compared to those treated in the medical ward (2.33&#xa0;&#xb1;&#xa0;2.57%). During hospitalization, FMD was inversely associated with Interleukin-6 and Troponin I (p&#xa0;&lt;&#xa0;0.05 for all). Although, a significant improvement in FMD was noted during the follow-up (acute: 1.75&#xa0;&#xb1;&#xa0;2.19% vs. 1&#xa0;month: 4.23&#xa0;&#xb1;&#xa0;2.02%, vs. 6&#xa0;months: 5.24&#xa0;&#xb1;&#xa0;1.62%; p&#xa0;=&#xa0;0.001), FMD remained impaired compared to control (6.48&#xa0;&#xb1;&#xa0;3.08%) at 1&#xa0;month (p&#xa0;&lt;&#xa0;0.001) and 6&#xa0;months (p&#xa0;=&#xa0;0.01) post-hospital discharge.</AbstractText><AbstractText Label="CONCLUSION">COVID-19 patients develop a notable endothelial dysfunction, which is progressively improved over a 6-month follow-up but remains impaired compared to healthy controls subjects. Whether chronic dysregulation of endothelial function following COVID-19 could be accompanied by a residual risk for cardiovascular and thrombotic events merits further research.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oikonomou</LastName><ForeName>Evangelos</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>3rd Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Sotiria Chest Disease Hospital, Athens, Greece; 1st Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Hippokration General Hospital, Athens, Greece. Electronic address: boikono@med.uoa.gr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Souvaliotis</LastName><ForeName>Nektarios</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>3rd Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Sotiria Chest Disease Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lampsas</LastName><ForeName>Stamatios</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>3rd Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Sotiria Chest Disease Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siasos</LastName><ForeName>Gerasimos</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>3rd Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Sotiria Chest Disease Hospital, Athens, Greece; 1st Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Hippokration General Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poulakou</LastName><ForeName>Garyphallia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>3rd Department of Medicine, Medical School, Sotiria Chest Disease Hospital, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Theofilis</LastName><ForeName>Panagiotis</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>1st Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Hippokration General Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papaioannou</LastName><ForeName>Theodore G</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>1st Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Hippokration General Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haidich</LastName><ForeName>Anna-Bettina</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Department of Hygiene, Social-Preventive Medicine and Medical Statistics, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsaousi</LastName><ForeName>Georgia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and ICU, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ntousopoulos</LastName><ForeName>Vasileios</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>3rd Department of Medicine, Medical School, Sotiria Chest Disease Hospital, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakka</LastName><ForeName>Vissaria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>3rd Department of Medicine, Medical School, Sotiria Chest Disease Hospital, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Charalambous</LastName><ForeName>Georgios</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Emergency Department, "Hippokration" General Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rapti</LastName><ForeName>Vasiliki</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>3rd Department of Medicine, Medical School, Sotiria Chest Disease Hospital, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raftopoulou</LastName><ForeName>Sylvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, Sotiria Chest Disease Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Syrigos</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>3rd Department of Medicine, Medical School, Sotiria Chest Disease Hospital, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsioufis</LastName><ForeName>Costas</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>1st Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Hippokration General Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tousoulis</LastName><ForeName>Dimitris</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>1st Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Hippokration General Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vavuranakis</LastName><ForeName>Manolis</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>3rd Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Sotiria Chest Disease Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Vascul Pharmacol</MedlineTA><NlmUniqueID>101130615</NlmUniqueID><ISSNLinking>1537-1891</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004730" MajorTopicYN="N">Endothelium, Vascular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014664" MajorTopicYN="N">Vasodilation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Endothelial function</Keyword><Keyword MajorTopicYN="N">Endothelium</Keyword><Keyword MajorTopicYN="N">Flow-mediated dilation</Keyword></KeywordList><CoiStatement>None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>6</Day><Hour>20</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35248780</ArticleId><ArticleId IdType="pmc">PMC8893931</ArticleId><ArticleId IdType="doi">10.1016/j.vph.2022.106975</ArticleId><ArticleId IdType="pii">S1537-1891(22)00024-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lazaros G., Oikonomou E., Theofilis P., et al. The impact of COVID-19 pandemic on adult cardiac surgery procedures. Hell. J. Cardiol. 2021;62:231&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7362781</ArticleId><ArticleId IdType="pubmed">32679176</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikonomou E., Aznaouridis K., Barbetseas J., et al. Hospital attendance and admission trends for cardiac diseases during the COVID-19 outbreak and lockdown in Greece. Public Health. 2020;187:115&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7434308</ArticleId><ArticleId IdType="pubmed">32949881</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassilikos V.P., Pagourelias E.D., Katsos K., et al. Impact of social containment measures on cardiovascular admissions and sudden cardiac death rates during coronavirus disease (COVID-19) outbreak in Greece. Hell. J. Cardiol. 2021;62:318&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7491429</ArticleId><ArticleId IdType="pubmed">32947022</ArticleId></ArticleIdList></Reference><Reference><Citation>Panagiotakos D., Tsiampalis T. Excess mortality in Greece during 2020: the role of COVID-19 and cardiovascular disease. Hell. J. Cardiol. 2021;62:378&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8022518</ArticleId><ArticleId IdType="pubmed">33836241</ArticleId></ArticleIdList></Reference><Reference><Citation>Cenko E., Badimon L., Bugiardini R., et al. Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on coronary pathophysiology &amp; microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA) Cardiovasc. Res. 2021;117:2705&#x2013;2729.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8500019</ArticleId><ArticleId IdType="pubmed">34528075</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsioufis C., Dimitriadis K., Tousoulis D. The interplay of hypertension, ACE-2 and SARS-CoV-2: emerging data as the &#x201c;Ariadne&#x2019;s thread&#x201d; for the &#x201c;labyrinth&#x201d; of COVID-19. Hell. J. Cardiol. 2020;61:31&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7242952</ArticleId><ArticleId IdType="pubmed">32450334</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga Z., Flammer A.J., Steiger P., et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417&#x2013;1418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172722</ArticleId><ArticleId IdType="pubmed">32325026</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia de Guadiana-Romualdo L., Calvo Nieves M.D., Rodriguez Mulero M.D., et al. MR-proADM as marker of endotheliitis predicts COVID-19 severity. Eur. J. Clin. Investig. 2021;51</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7995076</ArticleId><ArticleId IdType="pubmed">33569769</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaventura A., Vecchie A., Dagna L., et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat. Rev. Immunol. 2021;21:319&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8023349</ArticleId><ArticleId IdType="pubmed">33824483</ArticleId></ArticleIdList></Reference><Reference><Citation>Theofilis P., Sagris M., Oikonomou E., et al. Inflammatory mechanisms contributing to endothelial dysfunction. Biomedicines. 2021;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8301477</ArticleId><ArticleId IdType="pubmed">34356845</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans P.C., Rainger G.E., Mason J.C., et al. Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science. Cardiovasc. Res. 2020;116:2177&#x2013;2184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454368</ArticleId><ArticleId IdType="pubmed">32750108</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshmukh V., Motwani R., Kumar A., Kumari C., Raza K. Histopathological observations in COVID-19: a systematic review. J. Clin. Pathol. 2021;74:76&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">32817204</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasquez-Bonilla W.O., Orozco R., Argueta V., et al. A review of the main histopathological findings in coronavirus disease 2019. Hum. Pathol. 2020;105:74&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7395947</ArticleId><ArticleId IdType="pubmed">32750378</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin Z., Liu F., Blair R., et al. Endothelial cell infection and dysfunction, immune activation in severe COVID-19. Theranostics. 2021;11:8076&#x2013;8091.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8315069</ArticleId><ArticleId IdType="pubmed">34335981</ArticleId></ArticleIdList></Reference><Reference><Citation>Siasos G., Zografos T., Oikonomou E., Papavassiliou A.G., Stefanadis C., Tousoulis D. Flow-mediated dilation: is it just a research tool or a useful biomarker for cardiovascular prognosis. Int. J. Cardiol. 2015;180:154&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">25438239</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen D.H.J., Bruno R.M., van Mil A., et al. Expert consensus and evidence-based recommendations for the assessment of flow-mediated dilation in humans. Eur. Heart J. 2019;40:2534&#x2013;2547.</Citation><ArticleIdList><ArticleId IdType="pubmed">31211361</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y., Arora R.C., Hiebert B.M., et al. Non-invasive endothelial function testing and the risk of adverse outcomes: a systematic review and meta-analysis. Eur. Heart J. Cardiovasc. Imaging. 2014;15:736&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">24399339</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Therapeutic Trial Synopsis 2020. https://cdn.who.int/media/docs/default-source/blue-print/covid-19-therapeutic-trial-synopsis.pdf?sfvrsn=44b83344_1&amp;download=true [cited 2022 January 2]. Available from:</Citation></Reference><Reference><Citation>Thygesen K., Alpert J.S., Jaffe A.S., et al. Fourth universal definition of myocardial infarction (2018) Circulation. 2018;138:e618&#x2013;e651.</Citation><ArticleIdList><ArticleId IdType="pubmed">30571511</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V. Condition WHOCCDWGoP-C-. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Tousoulis D., Antoniades C., Stefanadis C. Evaluating endothelial function in humans: a guide to invasive and non-invasive techniques. Heart. 2005;91:553&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1768833</ArticleId><ArticleId IdType="pubmed">15772232</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianconi V., Mannarino M.R., Figorilli F., et al. Low brachial artery flow-mediated dilation predicts worse prognosis in hospitalized patients with COVID-19. J. Clin. Med. 2021;10:5456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8621380</ArticleId><ArticleId IdType="pubmed">34830738</ArticleId></ArticleIdList></Reference><Reference><Citation>Lampsas S., Tsaplaris P., Pantelidis P., et al. The role of endothelial related circulating biomarkers in COVID-19. A systematic review and meta-analysis. Curr. Med. Chem. 2021</Citation><ArticleIdList><ArticleId IdType="pubmed">34702152</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira M.R., Back G.D., da Luz Goulart C., Domingos B.C., Arena R., Borghi-Silva A. Endothelial function provides early prognostic information in patients with COVID-19: a cohort study. Respir. Med. 2021;185:106469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8141349</ArticleId><ArticleId IdType="pubmed">34175806</ArticleId></ArticleIdList></Reference><Reference><Citation>Heubel A.D., Viana A.A., Linares S.N., et al. Determinants of endothelial dysfunction in non-critically ill hospitalized COVID-19 patients: a cross-sectional study. Obesity (Silver Spring) 2021;30:165&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8661847</ArticleId><ArticleId IdType="pubmed">34554646</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsoularis I., Fonseca-Rodriguez O., Farrington P., Lindmark K., Fors Connolly A.M. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study. Lancet. 2021;398:599&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8321431</ArticleId><ArticleId IdType="pubmed">34332652</ArticleId></ArticleIdList></Reference><Reference><Citation>Santa Cruz A., Mendes-Frias A., Oliveira A.I., et al. Interleukin-6 is a biomarker for the development of fatal severe acute respiratory syndrome coronavirus 2 pneumonia. Front. Immunol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7930905</ArticleId><ArticleId IdType="pubmed">33679753</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridker P.M., Libby P., MacFadyen J.G., et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) Eur. Heart J. 2018;39:3499&#x2013;3507.</Citation><ArticleIdList><ArticleId IdType="pubmed">30165610</ArticleId></ArticleIdList></Reference><Reference><Citation>Esteve E., Castro A., L&#xf3;pez-Bermejo A., Vendrell J., Ricart W., Fern&#xe1;ndez-Real J.-M. Serum interleukin-6 correlates with endothelial dysfunction in healthy men independently of insulin sensitivity. Diabetes Care. 2007;30:939&#x2013;945.</Citation><ArticleIdList><ArticleId IdType="pubmed">17392554</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacchiega B.C., Bacchiega A.B., Usnayo M.J.G., Bedirian R., Singh G., Pinheiro GdRC. Interleukin 6 inhibition and coronary artery disease in a high-risk population: a prospective community-based clinical study. J. Am. Heart Assoc. 2017;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5524026</ArticleId><ArticleId IdType="pubmed">28288972</ArticleId></ArticleIdList></Reference><Reference><Citation>Vela D., Vela-Gaxha Z., Rexhepi M., Olloni R., Hyseni V., Nallbani R. Efficacy and safety of tocilizumab versus standard care/placebo in patients with COVID-19; a systematic review and meta-analysis of randomized clinical trials. Br. J. Clin. Pharmacol. 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8653234</ArticleId><ArticleId IdType="pubmed">34713921</ArticleId></ArticleIdList></Reference><Reference><Citation>Investigators R.-C., Gordon A.C., Mouncey P.R., et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N. Engl. J. Med. 2021;384:1491&#x2013;1502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7953461</ArticleId><ArticleId IdType="pubmed">33631065</ArticleId></ArticleIdList></Reference><Reference><Citation>Miwa K., Igawa A., Inoue H. Soluble E-selectin, ICAM-1 and VCAM-1 levels in systemic and coronary circulation in patients with variant angina. Cardiovasc. Res. 1997;36:37&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">9415270</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller W.A. Leukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory response. Trends Immunol. 2003;24:327&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pubmed">12810109</ArticleId></ArticleIdList></Reference><Reference><Citation>Spadaro S., Fogagnolo A., Campo G., et al. Markers of endothelial and epithelial pulmonary injury in mechanically ventilated COVID-19 ICU patients. Crit. Care. 2021;25:74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7894238</ArticleId><ArticleId IdType="pubmed">33608030</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrosino P., Calcaterra I., Molino A., et al. Persistent endothelial dysfunction in post-acute COVID-19 syndrome: a case-control study. Biomedicines. 2021;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8391623</ArticleId><ArticleId IdType="pubmed">34440161</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrosino P., Molino A., Calcaterra I., et al. Clinical assessment of endothelial function in convalescent COVID-19 patients undergoing multidisciplinary pulmonary rehabilitation. Biomedicines. 2021;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8226503</ArticleId><ArticleId IdType="pubmed">34071308</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambadiari V., Mitrakou A., Kountouri A., et al. Association of COVID-19 with impaired endothelial glycocalyx, vascular function and myocardial deformation 4 months after infection. Eur. J. Heart Fail. 2021;23:1916&#x2013;1926.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8426810</ArticleId><ArticleId IdType="pubmed">34415085</ArticleId></ArticleIdList></Reference><Reference><Citation>Jud P., Gressenberger P., Muster V., et al. Evaluation of endothelial dysfunction and inflammatory vasculopathy after SARS-CoV-2 infection-a cross-sectional study. Front. Cardiovasc. Med. 2021;8:750887.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8549830</ArticleId><ArticleId IdType="pubmed">34722682</ArticleId></ArticleIdList></Reference><Reference><Citation>Riou M., Oulehri W., Momas C., et al. Reduced flow-mediated dilatation is not related to COVID-19 severity three months after hospitalization for SARS-CoV-2 infection. J. Clin. Med. 2021;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8004847</ArticleId><ArticleId IdType="pubmed">33806800</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>